Skip to main content
OpenTrials

Clinical trial condition

Bronchial Neoplasms

Explore clinical trials studying Bronchial Neoplasms. Study availability and eligibility vary by location and protocol.

5,246 public trials 1,181 recruiting studies
Refine in advanced search Browse all conditions

Bronchial Neoplasms trial results

Active, Not Recruiting

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NCT06131398

Conditions
Advanced Solid Tumors, Bronchial Neoplasms, Carcinoma, Bronchogenic, +29 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • Alliance for Multispecialty Research - Kansas City Merriam, Kansas, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Washington University St Louis, Missouri, United States
View all 25 locations
View Trial Details
Active, Not Recruiting

A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

NCT05094336

Conditions
Advanced MTAP-null Solid Tumors, Biliary Tract Diseases, Biliary Tract Neoplasms, +29 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • California Research Institute Glendale, California, United States
  • Fomat Medical Research Oxnard, California, United States
  • University of California at SF San Francisco, California, United States
View all 75 locations
View Trial Details
Active, Not Recruiting

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

NCT06333951

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Comprehensive Blood and Cancer Center Bakersfield, California, United States
  • City of Hope National Medical Center Duarte, California, United States
  • City of Hope Orange County Lennar Foundation Cancer Center Duarte, California, United States
  • Translational Research in Oncology US Inc, Trio Central Pharmacy Los Angeles, California, United States
View all 83 locations
View Trial Details
Active, Not Recruiting

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

NCT05882734

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +19 more
Locations
  • UCLA Hematology and Oncology - Santa Monica Santa Monica, California, United States
  • UPMC Cancer Center Pittsburgh, Pennsylvania, United States
  • Tennessee Cancer Specialists - Biomedical Research Knoxville, Tennessee, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
View all 54 locations
View Trial Details
Active, Not Recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

NCT04514484

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Differentiated Thyroid Gland Carcinoma, +141 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • Montefiore Medical Center-Einstein Campus The Bronx, New York, United States
  • University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States
View Trial Details
Active, Not Recruiting

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

NCT04603807

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
Locations
  • Oncocentro Serviços Médicos e Hospitalares Ltda Fortaleza, Ceará, Brazil
  • Hospital Sao Rafael - HSR Salvador, Estado de Bahia, Brazil
  • Hospitais Integrados da Gavea S/A Brasília, Federal District, Brazil
  • Centro de Pesquisa e Ensino em Oncologia de Santa Catarina - CEPEN Florianópolis, Santa Catarina, Brazil
View all 61 locations
View Trial Details
Active, Not Recruiting

CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia

NCT05887011

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Research Site Arkhangelsk, Russia
  • Research Site Balashikha, Russia
  • Research Site Barnaul, Russia
  • Research Site Grozny, Russia
View all 37 locations
View Trial Details
Active, Not Recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT02568267

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Adnexal Diseases, +91 more
Locations
  • Dignity Health St Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • Mayo Clinic Phoenix, Arizona, United States
  • City of Hope Cancer Center Duarte, California, United States
  • City of Hope Duarte - Comprehensive Cancer Center, Investigational Drug Services Duarte, California, United States
View all 130 locations
View Trial Details
Active, Not Recruiting

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

NCT03392246

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Duke University Durham, North Carolina, United States
View Trial Details

Related conditions